
Daniel Jenkin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8659340/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
4	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
5	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
6	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
7	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
8	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
9	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
10	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
11	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
12	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
13	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	5.8	38
14	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nature Communications, 2021, 12, 4636.	5.8	31
15	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
16	Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). SSRN Electronic Journal, 0, , .	0.4	23
17	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022, 40, 5248-5262.	1.7	9
18	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine, 2022, 81, 104128.	2.7	8

#	Article	IF	CITATIONS
19	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 2021, 9, 262.	2.1	3
20	ls it time to consider IgG4-related disease in idiopathic retroperitoneal fibrosis?. Journal of Clinical Urology, 2017, 10, 222-224.	0.1	0